By: Bruce V. Bigelow
Source: Xconomy
Date: April 7, 2016

Xconomy San Diego – RiverVest Venture Partners has stayed mostly under the radar as a small-but-active investor in San Diego life sciences startups for the past 10 years or so.

After making investments in San Diego’s Cabrellis Pharmaceuticals and Conforma Therapeutics, the St. Louis, MO-based firm recruited Niall O’Donnell in 2006 to oversee the firm’s deals in San Diego.

O’Donnell, who was a Kauffman fellow and immunologist from Johnson & Johnson’s San Diego pharmaceutical R&D facility at the time, said his first deal came with the firm’s 2007 investment in Excaliard Pharmaceuticals, a Carlsbad, CA-based spinout from Ionis Pharmaceuticals (NASDAQ: IONS). Pfizer acquired Excaliard four years later at an undisclosed price.

Read Article

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Learn More